Biopharma company GenSight Biologics S.A. (Euronext Paris:SIGHT) announced on Wednesday that after five years of follow-up, Leber Hereditary Optical Neuropathy (LHON) subjects treated with LUMEVOQ (GS010) continued to experience significantly improved vision as a result of a one-time injection of the gene therapy treatment.
The large long-term follow-up study for a rare disease treatment, named RESTORE, involved 62 subjects accepting the invitation to enrol and 55 completing the study. All subjects, who were affected by LHON caused by a mutated ND4 mitochondrial gene, were treated with an intravitreal injection of LUMEVOQ in one eye and with sham injection in the other.
The company said that when compared to the trend in vision observed among untreated patients, the findings are a significant divergence from the natural outcomes of LHON, a rare maternally inherited mitochondrial genetic disease. LHON is characterised by the degeneration of retinal ganglion cells that results in irreversible vision loss that can lead to legal blindness. The disease mainly affects adolescents and young adults.
GenSight Biologics is focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer